Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: alector.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/14/2023 | $8.00 → $15.00 | Hold → Buy | Stifel |
12/12/2023 | $12.00 | Buy | Deutsche Bank |
9/25/2023 | $4.00 | Sell | Goldman |
9/22/2023 | $13.00 | Overweight | Cantor Fitzgerald |
1/6/2023 | $24.00 → $12.00 | Buy → Neutral | BofA Securities |
9/9/2022 | $27.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
7/7/2022 | $15.00 | Buy | Mizuho |
4/13/2022 | $9.00 | Sell | Goldman |
3/8/2022 | $32.00 → $18.00 | Buy → Hold | Stifel |
2/25/2022 | $43.00 → $40.00 | Buy | Citigroup |
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr. Kenkare-Mitra will lead all aspects of the company's immuno-neurology and oncology R&D efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Dr. Kenkare-Mitra will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. Dr. Kenkare-Mitra joins Alector from Genentech where, as Senior Vice President, Development S
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company's Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology. "Betsy is a highly-regarded leader with unmatched clinical development experience, particularly in neurodegenerative disease indications. As we advance our pipeline of novel immuno-neurology therapeutics into later-stage clinical trials, her expert perspec
144 - Alector, Inc. (0001653087) (Subject)
10-Q - Alector, Inc. (0001653087) (Filer)
8-K - Alector, Inc. (0001653087) (Filer)
8-K - Alector, Inc. (0001653087) (Filer)
10-Q - Alector, Inc. (0001653087) (Filer)
8-K - Alector, Inc. (0001653087) (Filer)
ARS - Alector, Inc. (0001653087) (Filer)
DEFA14A - Alector, Inc. (0001653087) (Filer)
DEF 14A - Alector, Inc. (0001653087) (Filer)
8-K - Alector, Inc. (0001653087) (Filer)
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Latozinemab, a novel investigational human monoclonal antibody, is the most advanced PGRN-elevating candidate in development for the treatment of FTD-GRN-- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on participant baseline characteristics for the pivotal INFRONT-3 Phase 3 clinical trial evaluating the safety and
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference (New York, New York) Thursday, September 5, 2024, at 7:45 a.m. ET, fireside chat H.C. Wainwright 26th Annual Global Investment Conference (New York, New York) Monday, September 9, 2024, at 10:00 a.m. ET, fireside chat 2024 Cantor Global Healthcare Conference (New York, New York) Tuesday, September 17, 2024, at 9:45 a.m. ET, fireside chat A webcast of each presentation will be ava
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the intended study population for testing the effects of AL002, a novel TREM2 agonist, in early AD The latozinemab pivotal INFRONT-3 Phase 3 trial continues to progress well, supported by a recent U.S. Food and Drug Administration interaction post Breakthrough Therapy Designation $503.3 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEW
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD-- SOUTH SAN FRANCISCO, Calif., July 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on baseline characteristics for the global INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowin
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. Poster presentations will be available for on-demand viewing beginning on July 28 at 8:00 a.m. ET. AL002 Presentations TREM2 Program (AL002) is Being Developed in Collaboration with AbbVie Poster Title: Baseline characteristics for INVOKE-2: a phase 2 randomized, double-blind, placebo-c
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5th Annual Neuro Perspectives Conference, being held virtually on Thursday, June 27, 2024. A webcast of the presentation will be available on the "Events & Presentations" page at 7:00 a.m. ET within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a clinical-stage biotechnology company pioneering im
SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB) technology platform that is being applied selectively to the Company's next-generation product candidates and research pipeline. The event will include a presentation from Alector's management team as well as a leading scientific expert who will offer insights into emerging technologies for BBB modulation and discuss future directions and opportunities in the field. Details of the webinar are as
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel ther
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 14, 2024, at 8:55 a.m. PT, corporate presentation H.C. Wainwright 2nd Annual BioConnect Investor Conference (New York, New York) Monday, May 20, 2024, at 11:00 a.m. ET, fireside chat A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alec
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:ALEC) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein reiterates Alector (NASDAQ:ALEC) with a Buy and maintains $35 price target.
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Monday. Shares of Perion Network Ltd. (NASDAQ:PERI) fell sharply in today's pre-market trading after the company lowered its revenue forecast. Perion Network slashed its second-quarter revenue forecast from $118 million – $122 million to $106 million – $108 million. The company lowered its FY24 revenue forecast from $590 million – $610 million to $490 million – $510 million. Perion Network shares dipped 21% to $9.74 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Skye Bioscience, Inc. (NASDAQ:SKYE) shares tumbled 45.2% to $6.00 in
HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers the price target from $41 to $35.
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector (NASDAQ:ALEC) with a Overweight.
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.51) by 25.49 percent. This is a 30.91 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $15.89 million which beat the analyst consensus estimate of $14.80 million by 7.39 percent. This is a 3.96 percent decrease over sales of $16.55 million the same period last year.
HC Wainwright & Co. analyst Andrew Fein reiterates Alector (NASDAQ:ALEC) with a Buy and maintains $41 price target.
Alector (NASDAQ:ALEC) reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Alector beat estimated earnings by 36.0%, reporting an EPS of $-0.49 versus an estimate of $-0.77. Revenue was up $750 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.13 which was followed by a 7.000000000000001% drop in the share price the next day. Here's a look at Alector's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.66 -0.81 -0.75 -0.46 EPS Actual -0.53 0.02 -0.55 -0.63 Revenue Estimate 9.97M 3.63M 7.96M 30.16M Revenue Ac
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.77) by 36.36 percent. This is a 22.22 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $15.19 million which beat the analyst consensus estimate of $9.64 million by 57.63 percent. This is a 5.19 percent increase over sales of $14.44 million the same period last year.
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the intended study population for testing the effects of AL002, a novel TREM2 agonist, in early AD The latozinemab pivotal INFRONT-3 Phase 3 trial continues to progress well, supported by a recent U.S. Food and Drug Administration interaction post Breakthrough Therapy Designation $503.3 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEW
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in Q1 2024 Latozinemab granted FDA's Breakthrough Therapy Designation for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN) Achieved target enrollment in pivotal INFRONT-3 latozinemab Phase 3 trial in FTD-GRN during Q4 2023 $620.0 million in cash, cash equivalents and investments after January 2024 equity offering anticipated to provide runway through 2026 Management to host conference c
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested partie
Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer's disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer's Association International Conference (AAIC) Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments provide runway through 2025; revenue and expense guidance updated for 2023 Management to host conference call and we
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Thursday, August 3, 2023, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2023, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties parti
Treatment with AL001 (latozinemab) demonstrated target engagement and resulted in increases in progranulin levels in all patients FTD-C9orf72 patients treated with latozinemab demonstrated a trend toward a delay in disease progression relative to the ALLFTD matched control cohort First clinical dataset in an indication where latozinemab elevated progranulin above physiological levels Company to host webcast to review results today at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced an oral presentation at the upcoming 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM) being held March 15-20, 2022 virtually and in person in Barcelona, Spain. Alector will present 12-month results from the INFRONT-2 Phase 2 open-label study of AL001 in the symptomatic cohort of Frontotemporal Dementia patients with a C9orf72 mutation. The Company plans to host a conference call to review these data on March 15, 2022, at 8:30 a.m. ET. Oral Presentation: Presentation Title: Twelve-M
Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain Atrophy FTD-GRN Patients Showed a Slowing of Clinical Progression with AL001 Treatment Relative to GENFI2 Matched Control Cohort Data from Phase 2 Study Presented at Clinical Trials of Alzheimer Disease Conference; Management to Host Webcast to Review Results Today at 4:00 p.m. ET BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented encouraging results from the company's INFRONT-2 Phase 2 clinical
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101 programs in poster presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 9-12, 2021, virtually and in Boston. "Since our formation, Alector has established a deep pipeline of therapeutic immuno-neurology candidates, each of which aims to harness the body's innate immune system to slow the progression of neurodegenerative diseases. The presentations at this year's CTAD conference highlight the diverse genetically validated targets we have in our p
Stifel upgraded Alector from Hold to Buy and set a new price target of $15.00 from $8.00 previously
Deutsche Bank initiated coverage of Alector with a rating of Buy and set a new price target of $12.00
Goldman initiated coverage of Alector with a rating of Sell and set a new price target of $4.00
Cantor Fitzgerald initiated coverage of Alector with a rating of Overweight and set a new price target of $13.00
BofA Securities downgraded Alector from Buy to Neutral and set a new price target of $12.00 from $24.00 previously
Morgan Stanley downgraded Alector from Overweight to Equal-Weight and set a new price target of $13.00 from $27.00 previously
Mizuho initiated coverage of Alector with a rating of Buy and set a new price target of $15.00
Goldman initiated coverage of Alector with a rating of Sell and set a new price target of $9.00
Stifel downgraded Alector from Buy to Hold and set a new price target of $18.00 from $32.00 previously
Citigroup reiterated coverage of Alector with a rating of Buy and set a new price target of $40.00 from $43.00 previously
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)